TY  - JOUR
T1  - The effect of long-term use of pioglitazone on bone mineral density in patients with diabetes mellitus
AU  - Durak, Muhammed Bahaddin
AU  - Yeşilaltay, Alpay
PY  - 2023
DA  - July
DO  - 10.38053/acmj.1318023
JF  - Anatolian Current Medical Journal
JO  - Anatolian Curr Med J / ACMJ / acmj
PB  - MediHealth Academy Yayıncılık
WT  - DergiPark
SN  - 2718-0115
SP  - 261
EP  - 265
VL  - 5
IS  - 3
LA  - en
AB  - Aims: This study aimed to explore the incidence of osteoporosis in patients with diabetes mellitus (DM) who have been on a long-term pioglitazone regimen, and to ascertain the link between pioglitazone usage and the onset of osteoporosis.Methods: We enrolled patients prospectively and conducted a comparative analysis between two groups of DM patients: those who had been using pioglitazone for a period exceeding two years, and those with no history of pioglitazone use. Bone Mineral Density (BMD) was assessed using dual energy X-ray absorptiometry (DEXA).Results: There were no significant differences in age, gender, disease duration, fasting plasma glucose levels, and HbA1c levels between pioglitazone users and non-users. However, a significant variation was found in the BMD measurements. Patients on pioglitazone had an L1-L4 vertebra BMD T-score of -1.3, compared to -0.9 in non-users (p
KW  - Pioglitazone
KW  - bone mineral density
KW  - diabetes mellitus
CR  - Green A, Hede SM, Patterson CC, et al. Type 1 diabetes in. 2017: global estimates of incident and prevalent cases in children and adults. Diabetologia. 2021;64(12):2741-2750.
CR  - Xu G, Liu B, Sun Y, et al. Prevalence of diagnosed type 1 and type 2 diabetes among US adults in. 2016 and. 2017: population based study. BMJ (Clinical research ed). 2018;362:k1497.
CR  - Merlotti D, Gennari L, Dotta F, et al. Mechanisms of impaired bone strength in type 1 and 2 diabetes. Nutr Metab Cardiovasc Dis. 2010;20(9):683-690.
CR  - Karjalainen J, Knip M, Hyoty H, et al. Relationship between serum insulin autoantibodies, islet cell antibodies and Coxsackie-B4 and mumps virus-specific antibodies at the clinical manifestation of type 1 (insulin-dependent) diabetes. Diabetologia. 1988;31 (3):146-152.
CR  - Brown SA, Sharpless JL. Osteoporosis: an under-appreciated complication of diabetes. Clinical Diabetes. 2004;22 (1):10-20.
CR  - Collino M, Aragno M, Castiglia S, et al. Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation. Br J Pharmacol. 2010;160(8):1892-1902.
CR  - Igarashi M, Hirata A, Yamaguchi H, et al. Pioglitazone reduces atherogenic outcomes in type 2 diabetic patients. J Atheroscler Thromb. 2008;15(1):34-40.
CR  - Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Pioglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2006;2006(4):CD006060.
CR  - Stunes AK, Westbroek I, Gustafsson BI, et al. The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats. BMC Endocr Disord. 2011;11:11.
CR  - Lecka-Czernik B. Bone loss in diabetes:use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporos Rep. 2010;8(4):178-184.
CR  - Takano M, Otsuka F, Matsumoto Y, et al. Peroxisome proliferator-activated receptor activity is involved in the osteoblastic differentiation regulated by bone morphogenetic proteins and tumor necrosis factor-alpha. Mol Cell Endocrinol. 2012;348(1):224-232.
CR  - Epstein M, Bakris G. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med. 1996;156(17):1969-1978.
CR  - Meymeh RH, Wooltorton E. Diabetes drug pioglitazone (Actos): risk of fracture. CMAJ. 2007;177(7):723-724.
CR  - Kanazawa I, Yamaguchi T, Yano S, et al. Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus. Osteoporos Int. 2010;21(12):2013-2018.
CR  - Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab. 2006;91(9):3349-3354.
CR  - Sottile V, Seuwen K, Kneissel M. Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcif Tissue Int. 2004;75(4):329-337.
CR  - Janghorbani M, Van Dam RM, Willett WC, et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166(5):495-505.
CR  - Yamamoto M, Yamaguchi T, Yamauchi M, et al. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res. 2009;24(4):702-709.
CR  - Huang S, Kaw M, Harris MT, et al. Decreased osteoclastogenesis and high bone mass in mice with impaired insulin clearance due to liver-specific inactivation to CEACAM1. Bone. 2010;46(4):1138-1145.
CR  - Krakauer JC, McKenna MJ, Buderer NF, et al. Bone loss and bone turnover in diabetes. Diabetes. 1995;44(7):775-782.
UR  - https://doi.org/10.38053/acmj.1318023
L1  - https://dergipark.org.tr/en/download/article-file/3224643
ER  -